The stock of Pfizer Inc. (NYSE:PFE) is a huge mover today! About 5.93M shares traded hands. Pfizer Inc. (NYSE:PFE) has risen 11.40% since March 9, 2016 and is uptrending. It has outperformed by 3.99% the S&P500.
The move comes after 9 months positive chart setup for the $197.73B company. It was reported on Oct, 12 by Barchart.com. We have $42.99 PT which if reached, will make NYSE:PFE worth $59.32 billion more.
Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on October, 25. They expect $0.62 EPS, up 3.33% or $0.02 from last year’s $0.6 per share. PFE’s profit will be $3.71B for 13.33 P/E if the $0.62 EPS becomes a reality. After $0.64 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -3.13% negative EPS growth.
Pfizer Inc. (NYSE:PFE) Ratings Coverage
Out of 18 analysts covering Pfizer (NYSE:PFE), 10 rate it a “Buy”, 0 “Sell”, while 8 “Hold”. This means 56% are positive. Pfizer has been the topic of 35 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Leerink Swann maintained the stock with “Market Perform” rating in Monday, May 2 report. Morgan Stanley upgraded Pfizer Inc. (NYSE:PFE) rating on Friday, October 2. Morgan Stanley has “Overweight” rating and $38 price target. Goldman Sachs maintained it with “Neutral” rating and $35 target price in Monday, April 18 report. The rating was maintained by Piper Jaffray on Friday, August 14 with “Buy”. The stock of Pfizer Inc. (NYSE:PFE) has “Hold” rating given on Wednesday, April 6 by Societe Generale. The firm has “Overweight” rating by Piper Jaffray given on Friday, August 28. The stock of Pfizer Inc. (NYSE:PFE) earned “Buy” rating by Deutsche Bank on Wednesday, October 28. The stock of Pfizer Inc. (NYSE:PFE) earned “Hold” rating by S&P Research on Wednesday, October 28. The rating was reinitiated by JP Morgan on Thursday, April 7 with “Overweight”. The stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given on Thursday, July 14 by Jefferies.
According to Zacks Investment Research, “Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.”
Insitutional Activity: The institutional sentiment decreased to 1.03 in 2016 Q2. Its down 0.21, from 1.24 in 2016Q1. The ratio fall, as 80 funds sold all Pfizer Inc. shares owned while 704 reduced positions. 127 funds bought stakes while 678 increased positions. They now own 4.15 billion shares or 5.76% less from 4.40 billion shares in 2016Q1.
Capital Guardian last reported 0.42% of its portfolio in the stock. Sun Life Financial Inc has invested 0.07% of its portfolio in Pfizer Inc. (NYSE:PFE). Rand Wealth Ltd Company owns 254,521 shares or 1.21% of their US portfolio. Country Tru Bank accumulated 780,795 shares or 1.48% of the stock. Meridian Mngmt, a Arkansas-based fund reported 35,561 shares. Amer State Bank last reported 160,878 shares in the company. Moreover, Conning has 1.57% invested in Pfizer Inc. (NYSE:PFE) for 1.08 million shares. Premier Asset Managment Limited Liability Corporation accumulated 0.42% or 46,646 shares. Convergence Partners Ltd Llc reported 131,293 shares or 0.64% of all its holdings. Marco Invest Mgmt Limited Liability Company has 1.07% invested in the company for 163,612 shares. Camarda Fin Advisors Limited Liability Corp last reported 84,104 shares in the company. Bragg Financial Advisors, a North Carolina-based fund reported 143,723 shares. Tyrian Invests Limited Partnership has 2.84% invested in the company for 79,400 shares. Private Financial Bank And Trust Co holds 62,643 shares or 0.34% of its portfolio. Blue Financial Capital Inc accumulated 42,622 shares or 1.24% of the stock.
Insider Transactions: Since May 3, 2016, the stock had 0 insider buys, and 13 selling transactions for $36.04 million net activity. Another trade for 4,700 shares valued at $157,450 was made by OLSON LAURIE J on Wednesday, May 11. Another trade for 29,600 shares valued at $1.00M was sold by HILL CHARLES H. SUSMAN SALLY sold 76,116 shares worth $2.57M. Another trade for 67,588 shares valued at $2.26 million was sold by Dolsten Mikael. On Tuesday, May 24 CANGIALOSI LORETTA V sold $2.92 million worth of the stock or 86,000 shares. YOUNG JOHN D sold $1.40M worth of Pfizer Inc. (NYSE:PFE) on Tuesday, May 10. DAMELIO FRANK A also sold $2.93M worth of Pfizer Inc. (NYSE:PFE) shares.
More recent Pfizer Inc. (NYSE:PFE) news were published by: Forbes.com which released: “Pfizer Divests Hospira Infusion Systems To ICU, Retaining An Interest In The …” on October 10, 2016. Also Fool.com published the news titled: “Better Buy: Pfizer Inc. vs. AbbVie Inc.” on September 15, 2016. Learnbonds.com‘s news article titled: “Pfizer Inc. (PFE) to Seek More Modern Headquarters in Manhattan” with publication date: October 07, 2016 was also an interesting one.
PFE Company Profile
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.